Pembrolizumab

• CAT Number: A001235
• CAS Number: 1374853-91-4
• Molecular Weight: 1296.4g/mol
• Purity: ≥95%
• IUPAC Name: 1-butyl-4-propylpiperazine;ethane;1-[hex-5-enyl(2-methyltetradecyl)amino]tetradecan-2-ol;3-[2-methylhexadeca-8,10-dienyl(2-methylhexadeca-9,11-dienyl)amino]propane-1-thiol
• InChI: 1S/C37H69NS.C35H71NO.C11H24N2.C2H6/c1-5-7-9-11-13-15-17-19-21-23-25-27-30-36(3)34-38(32-29-33-39)35-37(4)31-28-26-24-22-20-18-16-14-12-10-8-6-2;1-5-8-11-14-16-18-20-22-24-26-29-34(4)32-36(31-28-13-10-7-3)33-35(37)30-27-25-23-21-19-17-15-12-9-6-2;1-3-5-7-13-10-8-12(6-4-2)9-11-13;1-2/h11,13-18,20,36-37,39H,5-10,12,19,21-35H2,1-4H3;7,34-35,37H,3,5-6,8-33H2,1-2,4H3;3-11H2,1-2H3;1-2H3
• InChIKey: AMOIBCKFWIUEKF-UHFFFAOYSA-N
• SMILES: CC.CCCCCCCCCCCCC(C)CN(CCCCC=C)CC(CCCCCCCCCCCC)O.CCCCCC=CC=CCCCCCC(C)CN(CCCS)CC(C)CCCCCCC=CC=CCCCC.CCCCN1CCN(CC1)CCC

Pembrolizumab is a monoclonal antibody used in cancer immunotherapy. It works by inhibiting the PD-1 receptor on T-cells, enhancing the immune system’s ability to detect and attack tumor cells. Approved for multiple cancers, including melanoma, non-small cell lung cancer, and head and neck cancers, pembrolizumab has shown significant efficacy in improving survival outcomes. Ongoing studies are exploring its use in combination therapies and in treating other malignancies, establishing it as a cornerstone in cancer immunotherapy.